Striving to advance Alzheimer's disease drug development, the US FDA has revised its draft guidance to give sponsors more leeway in trial designs.
The new draft guidance, released on Feb. 15, specifies categories of patients based on different stages of disease progression, and notes the clinical endpoints acceptable for these stages. The...